We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 21, 2021

Increased Rates of Arterial Events, VTE, Thrombocytopenia, and Bleeding After Vaccination With Oxford–AstraZeneca ChAdOx1-S in Denmark and Norway

BMJ : British Medical Journal


Additional Info

BMJ : British Medical Journal
Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding After Vaccination With Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population Based Cohort Study
BMJ 2021 May 05;373(xx)n1114, A Pottegård, LC Lund, Ø Karlstad, J Dahl, M Andersen, J Hallas, Ø Lidegaard, G Tapia, HL Gulseth, PL Ruiz, SV Watle, AP Mikkelsen, L Pedersen, HT Sørensen, RW Thomsen, A Hviid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading